Use the hyperlinks, where available to access additional clinical trial information.
Single arm, open label, phase II trial of vemurafenib and cobimetinib in patients with metastatic non-squamous non-small cell lung cancer and other tumours harbouring BRAF V600 mutations detected by comprehensive genomic profiling
Australian Genomic Cancer Medicine Centre
In this randomised trial, participants will receive 2 drugs, vemurafenib and cobimetinib. Both drugs will be administered orally, at a dose of 960mg twice daily (days 1 to 28 in a 28-day cycle) for vemurafenib and 60mg daily (days 1-21 in a 28-day cycle) for cobimetinib. Participants will continue to receive treatment until toxicity or disease progression. Dosages may be reduced if participants experience toxicity.